Gaudana Ripal, Jwala J, Boddu Sai H S, Mitra Ashim K
Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, 5005 Rockhill Road, Kansas City, Missouri 64110-2499, USA.
Pharm Res. 2009 May;26(5):1197-216. doi: 10.1007/s11095-008-9694-0. Epub 2008 Aug 29.
Anatomy and physiology of the eye makes it a highly protected organ. Designing an effective therapy for ocular diseases, especially for the posterior segment, has been considered as a formidable task. Limitations of topical and intravitreal route of administration have challenged scientists to find alternative mode of administration like periocular routes. Transporter targeted drug delivery has generated a great deal of interest in the field because of its potential to overcome many barriers associated with current therapy. Application of nanotechnology has been very promising in the treatment of a gamut of diseases. In this review, we have briefly discussed several ocular drug delivery systems such as microemulsions, nanosuspensions, nanoparticles, liposomes, niosomes, dendrimers, implants, and hydrogels. Potential for ocular gene therapy has also been described in this article. In near future, a great deal of attention will be paid to develop non-invasive sustained drug release for both anterior and posterior segment eye disorders. A better understanding of nature of ocular diseases, barriers and factors affecting in vivo performance, would greatly drive the development of new delivery systems. Current momentum in the invention of new drug delivery systems hold a promise towards much improved therapies for the treatment of vision threatening disorders.
眼睛的解剖结构和生理机能使其成为一个受到高度保护的器官。为眼部疾病,尤其是眼后段疾病设计有效的治疗方法,一直被视为一项艰巨的任务。局部和玻璃体内给药途径的局限性促使科学家们寻找替代给药方式,如眼周给药途径。转运体靶向给药因其克服当前治疗相关诸多障碍的潜力而在该领域引起了极大关注。纳米技术在一系列疾病的治疗中前景十分广阔。在本综述中,我们简要讨论了几种眼部给药系统,如微乳剂、纳米混悬剂、纳米颗粒、脂质体、非离子表面活性剂泡囊、树枝状大分子、植入物和水凝胶。本文还描述了眼部基因治疗的潜力。在不久的将来,对于眼前段和眼后段眼部疾病,将高度重视开发非侵入性持续药物释放。对眼部疾病的本质、影响体内性能的屏障和因素有更好的理解,将极大地推动新给药系统的发展。新药递送系统发明的当前势头有望为治疗威胁视力的疾病带来显著改善的疗法。